ABSTRACT Background Percutaneous left atrial appendage occlusion (LAAO) is an alternative strategy for stroke prevention in patients with nonvalvular atrial fibrillation (AF) with contraindications to long‐term oral anticoagulation therapy. However, evidence comparing the long‐term outcomes of LAAO with those of direct oral anticoagulants (DOAC) remains limited. Methods A systematic search was conducted across PubMed, Scopus, and the Cochrane databases through April 2026. Co‐primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE; composite of cardiac death, stroke, or systemic embolism) and net adverse clinical events (NACE; composite of MACCE and non‐procedure‐related bleeding). Secondary endpoints included individual components of co‐primary endpoints, ischemic and hemorrhagic stroke, all‐cause death, major or clinically significant bleeding (procedure + non‐procedure related), and stroke or systemic embolism. The random‐effects model was used to generate risk ratios (RRs) and 95% CIs. Results Four randomized controlled trials comprising 5890 AF patients and a median follow‐up of 3 years were included. There was no significant difference between LAAO and DOAC therapy in the risk of MACCE (RR 1.17; 95%CI 0.96–1.41; I 2 = 0%) or NACE (RR 0.89; 95%CI 0.65–1.24; I 2 = 85%). Both LAAO and DOAC therapy were similar in risk of cardiac death, stroke, systemic embolism, hemorrhagic stroke, ischemic stroke, all‐cause mortality, stroke or systemic embolism, and pericardial effusion. LAAO was associated with a lower risk of non‐procedure‐related bleeding (RR 0.60; 95%CI 0.47–0.76; I 2 = 59%). Conclusion LAAO demonstrated efficacy comparable to DOAC therapy in reducing the risk of MACCE, NACE, and ischemic events, while significantly reducing the risk of non‐procedure‐related bleeding. Our findings support a tailored approach to stroke prevention in AF, wherein LAAO serves as an effective alternative for patients with contraindications to DOAC therapy.
Catheter Ablation Versus Medical Therapy as First‐Line Treatment for Ventricular Electrical Storm: A Systematic Review and Meta‐Analysis
ABSTRACT Background Electrical storm (ES) is a life‐threatening manifestation of recurrent ventricular arrhythmia. While anti‐arrhythmic drugs (AADs) have historically been the first‐line treatment, the role of catheter ablation (CA) as an initial therapy in ES remains incompletely defined. This meta‐analysis evaluates the efficacy and safety of radiofrequency CA compared to escalating medical therapy in patients with ES. Methods A systematic search of PubMed, Science Direct, and Cochrane databases was conducted for studies published from 2010 to 2025 that compared CA with medical therapy as first‐line treatment for ES. Outcomes of interest included ES recurrence, ventricular arrhythmia recurrence, in‐hospital mortality, procedural complications, and follow‐up survival. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Results Six studies encompassing 963 patients (473 CA, 490 medical therapy) were included. The mean age was 67.8 years, and 87.7% were male. The mean left ventricular ejection fraction was 33%, and ischemic cardiomyopathy was present in 77.5% of CA and 72.1% of MT patients. CA reduced the risk of ES recurrence by 71% compared to medical therapy (OR: 0.29; 95% CI: 0.15–0.53; p < 0.001; I ² = 53%). Recurrence of any ventricular arrhythmia, in‐hospital mortality, and long‐term survival were also significantly improved with CA. Conclusion This meta‐analysis suggests that CA is associated with lower ES and VA recurrence and in‐hospital mortality and improved survival compared to medical therapy alone. These findings support consideration of catheter ablation as a first‐line strategy. Larger prospective trials are needed to confirm these findings and guide patient selection.